Core Viewpoint - The article discusses the recent IPO counseling filings of seven companies, highlighting their business focus, financial performance, and challenges faced in the IPO process. Group 1: Company Profiles - Jinlong New Materials specializes in military tents and camping supplies, with a production capacity of 10 million sets of binding materials and 100,000 tents annually [4][5] - Saikesaisi, a high-tech enterprise in the field of biomedical materials, has faced multiple IPO application failures and regulatory warnings due to internal control issues [9][10] - Guodian Cable focuses on the research, production, and sales of electric cables, reporting increasing revenue but declining profits [15] - Oushangyuan is an organic acid equipment supplier aiming for an IPO on the ChiNext board, with a focus on technology design and equipment supply [18][19] - Xinghe Power, a commercial aerospace company, has achieved significant milestones in satellite launches and is valued at over 150 billion RMB [25][26] - Bangsheng Technology, a big data software developer, has previously attempted to list on the Sci-Tech Innovation Board but withdrew its application [30][31] - Kangbaijia Pharmaceutical operates over 2,000 stores, primarily in Fujian, and has recently expanded through acquisitions [35] Group 2: Financial Performance - Jinlong New Materials has a registered capital of 100.9 million RMB and is controlled by its founder, holding 68.31% of the shares [4][5] - Saikesaisi's revenue from 2021 to 2023 was 437 million, 436 million, and 379 million RMB, with net profits showing a slight increase followed by a decline [10] - Guodian Cable's projected revenues for 2023 and 2024 are 1.548 billion and 2.055 billion RMB, respectively, with net profits of 94.05 million and 77.92 million RMB, indicating a situation of increasing revenue but decreasing profit [15] - Bangsheng Technology reported revenues of 101 million, 196 million, and 270 million RMB from 2020 to 2022, with net losses each year [31] Group 3: IPO Challenges - Saikesaisi has faced regulatory scrutiny and warnings from the Shenzhen Stock Exchange, leading to the withdrawal of its IPO application in 2025 [9][10] - Guodian Cable's financial performance raises concerns about its ability to attract investors due to the increase in revenue without corresponding profit growth [15] - Bangsheng Technology's previous attempt to list on the Sci-Tech Innovation Board was unsuccessful, leading to a renewed effort for an IPO [30][31]

Summary of Key Points Core Viewpoint - This week, three new stocks are available for subscription in the A-share market, including Hanbang Technology, Weigao Blood Purification, and Taili Technology [1][2]. Group 1: Hanbang Technology - Hanbang Technology is a leading company in chromatography equipment in China, with a subscription code of 787755 and an issue price of 22.77 yuan per share, with a P/E ratio of 26.35 times [3][6]. - The total number of shares issued is 22 million, with 5.28 million shares available for online subscription. The maximum subscription limit for investors is 5,000 shares, requiring a market value of 50,000 yuan in the Shanghai market [3][6]. - The company’s revenue is projected to grow from 482 million yuan in 2022 to 691 million yuan in 2024, with net profits increasing from 38.56 million yuan to 79.34 million yuan during the same period [7][10]. - Major clients include domestic pharmaceutical companies and international clients such as INTECH ANALYTICAL INSTRUMENTS and REETEC AS [7]. Group 2: Weigao Blood Purification - Weigao Blood Purification is a manufacturer of medical products for blood purification, with a subscription code of 732014. The total number of shares issued is 41.14 million, with 11.11 million shares available for online subscription [12][14]. - The company’s revenue is expected to rise from 3.426 billion yuan in 2022 to 3.604 billion yuan in 2024, with net profits increasing from 315.00 million yuan to 449.39 million yuan [12][14]. - Key clients include major pharmaceutical groups such as China National Pharmaceutical Group and China Resources Group [12]. Group 3: Taili Technology - Taili Technology focuses on new material research and vacuum technology applications, with a subscription code of 301595. The total number of shares issued is 27.07 million, with 6.90 million shares available for online subscription [17]. - The company’s revenue is projected to grow from 638 million yuan in 2022 to 1.020 billion yuan in 2024, with net profits increasing from 58.84 million yuan to 87.64 million yuan [17][18]. - Major clients include international retailers such as IKEA and Walmart, with Taili Technology being the exclusive supplier of vacuum bags for China's aerospace applications [17].

近年来，中国色谱市场正经历明显的"冰火两重天"局面：一方面，国内市场持续疲软，市场竞争日益激烈，中小企业生存承压；另一方面，国 产替代浪潮加速，头部企业融资频获突破，技术应用场景持续深化。在此背景下， ACCSI 2 0 2 5色谱新应用场景及产业生态升级发展论坛 将于 2 0 2 5年5月1 2日下午 在上海松江区富悦大酒店召开。论坛将汇聚行业领军者、顶级专家及产业链上下游代表，共同探讨中国色谱技术突围路径 与市场机遇。 点击报名参会 核心亮点抢先看 亮点一 聚焦细分市场突围，解码国产替代行业机遇 在中美关税战升级与政策强驱动下，色谱下游应用行业对降本增效、国产设备的迫切需求成为关键推力。特别是主流应用市场——制药与石化 领域成为破局关键。论坛将深度解析细分市场动态，邀请业内权威专家结合政策红利与行业痛点，探讨行业应用现状于需求，探讨国产色谱如 何从实现大市场的"国产替代"。 导读： 聚焦色谱技术，探讨国产替代机遇与产业升级路径，共话行业发展新趋势。ACCSI 2025色谱新应用场景及产业生态升级发展论坛将于2025年5月12日下午 在上海松江区富悦大酒店召开。 特别提示 微信公众号机制调整，请点击顶部"仪 ...